IRIS
SICURANZA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.094
NA - Nord America 3.868
AS - Asia 2.223
SA - Sud America 399
AF - Africa 130
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.726
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.782
RU - Federazione Russa 1.114
SG - Singapore 740
GB - Regno Unito 735
CN - Cina 615
IT - Italia 590
IE - Irlanda 526
BR - Brasile 335
DE - Germania 281
VN - Vietnam 256
SE - Svezia 212
FR - Francia 204
HK - Hong Kong 175
FI - Finlandia 167
UA - Ucraina 96
KR - Corea 91
IN - India 87
ZA - Sudafrica 71
CA - Canada 49
BD - Bangladesh 33
JP - Giappone 30
NL - Olanda 29
AR - Argentina 26
TR - Turchia 25
IQ - Iraq 24
PK - Pakistan 24
ES - Italia 23
MX - Messico 23
PL - Polonia 23
AT - Austria 19
IR - Iran 19
CZ - Repubblica Ceca 16
EG - Egitto 15
SA - Arabia Saudita 14
BE - Belgio 13
ID - Indonesia 10
KE - Kenya 10
CO - Colombia 9
NG - Nigeria 9
UZ - Uzbekistan 9
AU - Australia 8
MA - Marocco 8
MY - Malesia 6
PH - Filippine 6
AZ - Azerbaigian 5
BG - Bulgaria 5
CH - Svizzera 5
CI - Costa d'Avorio 5
CL - Cile 5
DZ - Algeria 5
EC - Ecuador 5
ET - Etiopia 5
JO - Giordania 5
KH - Cambogia 5
LT - Lituania 5
PT - Portogallo 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
GR - Grecia 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NP - Nepal 4
PE - Perù 4
PY - Paraguay 4
UY - Uruguay 4
EE - Estonia 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
OM - Oman 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
CR - Costa Rica 2
EU - Europa 2
GE - Georgia 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MN - Mongolia 2
PS - Palestinian Territory 2
TH - Thailandia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DK - Danimarca 1
GD - Grenada 1
HN - Honduras 1
JM - Giamaica 1
LU - Lussemburgo 1
MK - Macedonia 1
MM - Myanmar 1
NO - Norvegia 1
Totale 10.722
Salva come PNG Salva come JPEG
Città #
Southend 624
Dallas 556
Dublin 521
Singapore 470
Fairfield 368
Ashburn 323
Moscow 307
Santa Clara 210
Chandler 185
Hong Kong 168
Munich 163
San Jose 158
Woodbridge 158
Beijing 157
Hefei 157
Siena 145
Seattle 128
Wilmington 125
Helsinki 120
Cambridge 108
Houston 103
Ann Arbor 96
Seoul 90
Ho Chi Minh City 81
The Dalles 79
New York 78
Los Angeles 75
Jacksonville 73
Lauterbourg 70
Princeton 63
Hanoi 61
Johannesburg 61
Milan 61
Council Bluffs 56
Florence 54
São Paulo 45
Dong Ket 31
Nanjing 29
London 27
Rome 26
Redondo Beach 25
Shanghai 25
Tokyo 25
Orem 24
Bengaluru 23
Frankfurt am Main 23
Dearborn 22
Chennai 21
Nuremberg 21
Turku 21
Buffalo 20
Denver 17
San Mateo 17
Warsaw 17
Da Nang 16
Düsseldorf 16
San Diego 16
Boardman 15
Izmir 15
Portsmouth 15
Toronto 15
Washington 14
Lappeenranta 13
Brussels 12
Messina 12
Montreal 12
Stockholm 12
San Francisco 11
Turin 11
Baghdad 10
Brno 10
Brooklyn 10
Chicago 10
Guangzhou 10
Mumbai 10
Vienna 10
Abuja 9
Atlanta 9
Poplar 9
Rio de Janeiro 9
Haiphong 8
Porto Alegre 8
Tashkent 8
Amsterdam 7
Belo Horizonte 7
Biên Hòa 7
Boston 7
Cairo 7
Columbus 7
Dhaka 7
Fremont 7
Nanchang 7
Shenyang 7
Guarulhos 6
Jinan 6
Kunming 6
Phoenix 6
Querétaro 6
Tianjin 6
Abidjan 5
Totale 7.157
Salva come PNG Salva come JPEG
Nome #
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 316
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 305
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 302
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 291
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 288
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 288
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 288
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 285
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 276
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 267
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 248
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 243
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 240
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 240
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 232
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 229
Peptide vaccines for hematological malignancies: a missed promise? 227
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 226
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 225
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 222
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 204
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 201
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 200
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 192
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 189
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 188
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 184
Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma 182
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden 177
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 172
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 170
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) 160
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 152
Drug resistance and minimal residual disease in multiple myeloma 151
DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response/MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study 150
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 149
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 146
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 145
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 139
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 138
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 137
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 133
Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow 133
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 129
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 127
Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma 126
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy 125
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia 124
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 123
CD26/DPP-4 in Chronic Myeloid Leukemia 123
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis 122
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia 118
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies 110
The role of tumor-associated macrophages in hematologic malignancies 110
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 99
Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation 98
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies 97
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 67
Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience 51
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers 49
Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML) 27
Reply to “Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!” 21
Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries 17
VEXAS syndrome and cancer: Insights about a possible “Tip of the Iceberg”. Ambidirectional data from the international AIDA network registries 16
Totale 10.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.848
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.848
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021224 0 0 0 0 0 0 0 0 0 89 52 83
2021/2022609 42 71 33 55 39 18 26 18 42 41 108 116
2022/2023834 42 94 106 82 60 130 30 86 76 11 94 23
2023/20241.026 31 32 95 62 53 246 330 23 12 41 23 78
2024/20251.937 35 61 215 99 205 134 104 129 211 116 209 419
2025/20264.324 337 590 480 662 1.044 181 471 130 148 281 0 0
Totale 10.909